JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus
Sign Up to like & getrecommendations! Published in 2017 at "Experimental Dermatology"
DOI: 10.1111/exd.13253
Abstract: This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2‐kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho‐JAK2 in CLE skin samples… read more here.
Keywords: inhibitor ruxolitinib; ruxolitinib; jak inhibitor; ruxolitinib inhibits ... See more keywords